Seeking Alpha

ASCO oncology conference: Medivation (MDVN -0.6%) and partner Astellas (ALPMY.PK) say their...

ASCO oncology conference: Medivation (MDVN -0.6%) and partner Astellas (ALPMY.PK) say their enzalutamide drug for advanced prostate cancer met secondary endpoints in a Phase 3 study. Medivation last month said it has applied for FDA approval to use enzalutamide in men with advanced prostate cancer who had undergone chemo. (see Zytiga)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|